低分期上尿路上皮癌根治手术不加膀胱袖状切除的可行性分析

目的 分析低分期肾盂及中上段输尿管尿路上皮癌行根治性肾切除术与经典肾盂癌根治性手术后肿瘤复发率的差异,探讨低分期上尿路上皮癌患者不行膀胱袖状切除的可行性.方法 回顾性分析2000-2007年收治73例上尿路上皮癌患者的资料.男36例,女37例.平均年龄66(45～87)岁.其中肾盂癌46例,中上段输尿管癌27例.根据术式分为经典肾盂癌根治性手术组(35例)和根治性肾切除组(38例).分析2组患者病理及随访结果,比较2组患者术后复发率的差异.结果 经典肾盂癌根治性手术组肿瘤复发8例(22.9%),其中T1患者复发率20.0%(3/15);根治性肾切除组肿瘤复发8例(21.1%),其中T1患者复发率19.0%(4/21),2组总复发率和T1肿瘤复发率差异无统计学意义(P>0.05).经典肾盂癌根治性手术组19例肾盂癌中,肿瘤复发4例(21.1%);16例中上段输尿管癌中,肿瘤复发4例(25.0%),2组肿瘤复发率差异无统计学意义(P>0.05).根治性肾切除组27例肾盂癌中,肿瘤复发3例(11.1%);11例中上段输尿管癌中,肿瘤复发5例(45.5%),2组肿瘤复发率差异有统计学意义(P<0.05).结论 低分期上尿路上皮癌患者可不行膀胱袖状切除术,但肿瘤位于输尿管者应行膀胱袖状切除术.     

后腹腔镜联合经尿道电切镜治疗上尿路移行细胞癌(附83例报告)

目的 探讨后腹腔镜联合经尿道电切镜治疗上尿路移行细胞癌的效果和安全性. 方法 2003年3月～2006年7月,我院采用后腹腔镜联合经尿道电切镜治疗83例上尿路移行细胞癌.经尿道袖状电切患侧输尿管口周围1.5 cm范围膀胱壁达膀胱外脂肪组织,采用后腹腔镜切除肾及全长输尿管.术后留置导尿管7 d.11例术后辅助放疗. 结果 83例手术均成功.手术时间115～205 min,平均156 min.术中出血50～150 ml,平均80 ml.无术中并发症.术后住院7～11 d,平均8.5 d.病理报告：82例上尿路移行细胞癌,1例肾盂上皮中～重度不典型增生.术后随访3～38个月,平均10.8月.术后12个月内行膀胱镜检查发现膀胱肿瘤6例,其中5例行经尿道膀胱肿瘤电切,1例行腹腔镜根治性膀胱全切术、左侧输尿管皮肤造口术.2例肾盂肿瘤（pT3 G3和pT2 G3）于术后3个月肝转移.2例输尿管中段肿瘤（pT3 G3和pT3 G2～3）术后6个月原位复发并肺转移.1例输尿管下段肿瘤（pT3 G3）术后6个月骨转移.失访1例.其余71例均未发现肿瘤复发、切口转移及远处转移. 结论 对于上尿路移行细胞癌,采用后腹腔镜联合经尿道电切镜行肾、输尿管全切及膀胱袖套状切除具有创伤小、安全、恢复快等优点,值得临床推广应用.     

双侧上尿路同时发生移行细胞癌6例报告

目的:探讨双侧上尿路同时发生移行细胞癌患者的处理方法。方法:报告6例双侧上尿路同时发生移行细胞癌患者的临床资料,均有慢性肾功能不全、无痛性肉眼血尿,经影像学和输尿管镜等检查确诊。3例行保肾手术,2例行肾输尿管切除术,1例仅行活检术。结果:术后病理检查均为移行细胞癌。随访3~33个月,平均14.2个月。随访期间2例死亡,2例术后发生膀胱肿瘤,1例输尿管肿瘤复发,2例未见肿瘤复发。结论:双侧上尿路同时发生移行细胞癌,根据肾功能情况可选择行保肾手术或双侧肾输尿管切除术;保肾手术后应加强监测,以利早期发现复发和治疗。     

腹腔镜根治性肾输尿管切除术治疗上尿路肿瘤

目的:评价腹腔镜根治性肾输尿管切除术治疗上尿路移行细胞癌的有效性和安全性.方法:对26例上尿路肿瘤患者,其中2例曾有同侧肾移植史,行腹腔镜根治性肾输尿管切除及膀胱黏膜袖套状切除术,并记录其有关指标.结果:26例均手术成功,其中3例采用经腹腔途径,23例经后腹腔途径.平均手术时间120 min,术中出血量46 ml,术后住院时间10.5 d,恢复正常活动时间4.1周.20例随访6～38个月,1例局部腹膜后肿瘤复发,1例膀胱内复发;无远处转移及穿刺通道的种植性转移.结论:腹腔镜根治性肾输尿管切除术治疗上尿路移行细胞癌是安全、有效的微创手术方法,但其对肿瘤细胞生物学行为的影响尚需作进一步的评价.     

内镜下钬激光治疗早期上尿路上皮肿瘤特殊病例1O例报告

目的探讨内镜下钬激光治疗特殊早期上尿路上皮肿瘤的安全性及有效性。方法2002年4月～2010年5月,对10例不适合行根治性。肾输尿管切除术的早期上尿路上皮肿瘤患者行内镜下钬激光治疗,其中输尿管肿瘤7例（1例合并膀胱肿瘤）,肾盂肿瘤3例。单发7例,多发3例。术前肿瘤分期cTa～cT1。3例对侧已行肾输尿管全长切除,2例孤立肾,3例肾功能不全,1例2～3级心功能不全,1例肿瘤小（〈1cm,位于。肾盂,单发且表浅）。输尿管硬镜治疗7例,软镜1例,微通道经皮肾镜2例。术后行丝裂霉素上尿路及膀胱灌注化疗。结果10例术后随访2年,无肿瘤死亡。1例术后6个月输尿管狭窄,其余均未出现大出血、严重感染、周围脏器损伤及全身肿瘤转移。复发4例,其中1例输尿管合并膀胱肿瘤者膀胱内复发,1例为肾盂内单发肿瘤复发,2例为输尿管单发肿瘤复发。该4例随访5年,1例未见肿瘤复发与转移,3例复发3—4次,且为尿路多处复发,行肾盂输尿管癌根治术,其中2例术后血液透析1年内肿瘤转移死亡。结论对不适合行根治性肾输尿管切除术的早期上尿路上皮肿瘤,内镜下钬激光治疗短期内是安全有效的。     

孤立肾上尿路移行细胞癌治疗策略

目的探讨孤立肾上尿路移行细胞癌的治疗对策。方法回顾分析5例孤立肾上尿路移行细胞癌患者的临床资料,所有患者行手术治疗。其中4例患者行保肾手术,1例行开放手术,3例行腔内技术治疗。结果5例患者手术均顺利得到随访,时间2个月～60个月,平均21个月。1例肾盂癌患者于术后2个月死于肺部疾病,1例肾盂癌术后19个月肿瘤局部并膀胱复发死于尿毒症,1例肾盂癌伴输尿管癌于术后25个月死于肿瘤转移,另2例无瘤存活。结论孤立肾上尿路移行细胞癌是施行保肾手术的适应症,采用腔内手术治疗是一种安全和可行的术式。保肾手术后应行肾盂灌注化疗预防肿瘤复发并长期随访。     

膀胱全切原位尿流改道术治疗膀胱非尿路上皮癌的疗效评价

目的：评价膀胱全切原位尿流改道术治疗膀胱非尿路上皮癌的疗效.方法：对17例膀胱非尿路上皮癌患者行根治性膀胱全切,盆腔淋巴结清扫;然后取一段肠管缝制成新膀胱,分别与输尿管和尿道残端吻合,实现原位尿流改道.结果：手术均获成功,手术时间172～380 min,平均310 min.16例获得随访,平均随访67个月（1～16年）.6例因肿瘤复发或转移于5年内死亡,2例死于非肿瘤因素,1例仍在随访,7例存活已达5年.结论：根治性膀胱全切原位尿流改道术治疗膀胱非尿路上皮癌,具有较好的治疗效果,能明显改善患者生活质量.     

同侧肾盂尿路上皮癌并发鳞状细胞癌的诊疗分析

目的探讨同侧肾盂尿路上皮癌并发鳞状细胞癌的临床特点及诊疗经验。方法回顾性分析4例该病患者的临床资料:3例临床表现为腰部或胁肋部不适、隐痛或胀痛,1例因血尿发现,4例均有患侧肾结石病史(20~45年,平均30年);伴发热者2例,左侧骶髂关节疼痛者1例,右侧第6肋骨疼痛者1例;血清结核DNA均1000IU/ml;行CT检查4例,IVU检查3例,B超检查3例,KUB检查1例,全身骨扫描2例。术前诊断为肿瘤1例,误诊为结核1例,诊断为肾多发结石2例;肾结石术中发现肿瘤并经快速冰冻病理确诊2例。4例患者均经手术治疗,行根治性肾输尿管全切除者3例,根治性肾切除者1例。结果 4例患者病理诊断均为尿路上皮癌并发鳞状细胞癌,其中低分化3例、中分化1例,T_3N_1M_0者2例、T_3N_1M_1者1例、T_4N_2M_1者1例。术后均获随访,生存时间50天~14个月,中位生存时间5个月,患者均死于肿瘤复发及转移。结论 CT、IVU检测对于肾盂尿路上皮癌并发鳞状细胞癌的诊断具有重要意义,根治性肾输尿管全切除术是治疗本病的较好方法,但本病预后极差。     

后腹腔镜联合尿道电切镜根治性肾输尿管切除治疗上尿路移行细胞癌(附16例报告)

目的 探讨后腹腔镜联合尿道电切镜根治性肾输尿管切除治疗上尿路移行细胞癌的方法和临床疗效. 方法 对10例肾盂癌、6例输尿管上中段移行细胞癌先采用尿道电切镜行患侧输尿管口膀胱黏膜袖套状切除,而后行后腹腔镜根治性肾输尿管全切术. 结果 16例手术均获成功,平均手术时间120 min,术中出血平均80 ml,患者均于术后36～48 h下床活动,术后住院时间8～14 d(平均9.4 d),术后随访膀胱局部复发2例. 结论 后腹腔镜联合尿道电切镜根治性肾输尿管切除治疗上尿路肿瘤是一种安全、有效的微创手术方法,实用性较强,具有良好的应用前景.     

双侧上尿路肿瘤的治疗方法分析与评估(附2例报告)

目的 探讨双侧上尿路同时发生恶性肿瘤的治疗方法及有效性评价.方法 报告2013年1月～2013年2月本院收治的2例双侧上尿路同时发生肿瘤患者的临床资料,2例均行一侧肾输尿管全长切除术,对侧保留肾脏的手术.其中1例为输尿管膀胱再吻合术,1例为输尿管镜下肿瘤切除术.结果 术后病理结果均提示移行细胞癌.目前2例患者均在随访中,其中1例术后6个月及8个月分别出现膀胱肿瘤复发,后于2013年10月行膀胱根治性切除术;1例未见肿瘤复发.结论 对于双侧同时存在尿路上皮肿瘤的患者,可根据实际情况选择一侧肾输尿管全长切除+对侧保留肾脏的手术方法,此种治疗方式术后花费低、患者主观生存质量较高,值得临床推荐.当然术后有效的随访必不可少.     

Endoscopic ureteral procedures for one-step nephroureterectomy: experience in 100 cases

BACKGROUND AND PURPOSE: Nephroureterectomy with perimeatal cystectomy is the gold standard for the treatment of urothelial upper urinary-tract carcinoma (UUTC). Ureteral endoscopic surgery has been proposed as a complementary step in nephroureterectomy, either open or laparoscopic, in order to obviate the low abdominal incision. Our goal was to establish the value of two techniques for endoscopic distal-ureteral management in one-step nephroureterectomy for UUTC. PATIENTS AND METHODS: Between June 1995 and January 2006, 100 nephroureterectomies with an endoscopic distal ureteral approach were performed for UUTC (stage pT(a) in 31 cases, pT1 in 27 cases, pT2 in 21 cases, pT3 in 18 cases, and pT(4) in 3 cases). The tumor was pyelocaliceal in 65 cases, ureteral in 18 cases, and both ureteral and pyelocaliceal in 17 cases. Among the patients, 72 underwent "pluck" transurethral detachment of the intramural ureter, and 28 were managed by ureteral stripping. The follow-up was performed by cystoscopy with urinary cytology, ultrasonography, and intravenous urography. The mean follow-up was 44 months (range 4-129 months). RESULTS: All but two of the procedures were completed successfully. In these two patients, ureteral stripping failed, and open surgery was performed. The complication rate was 2.8% for the pluck technique and 7.1% for ureteral stripping. During follow-up, 23 patients had bladder recurrences, 2 had renal fossa tumors, 3 had secondary lymph-node invasion, 2 had contralateral UUTC, and 1 had asynchronous liver metastases. The disease-specific mortality rate was 12%. CONCLUSIONS: The endoscopic approach to the terminal ureter is safe and effective as part of one-step nephroureterectomy. Differences between the techniques with regard to operative time, complications, and oncologic outcome were not significant.     

选择性应用保留肾脏术式治疗原发性输尿管癌

目的探讨在输尿管癌患者中选择性应用保留肾脏术式的可行性及其疗效。方法回顾性分析我院2004年5月至2012年5月应用保留。肾脏术式治疗原发性输尿管癌13例患者资料,其中男性7例,女性6例,年龄43～76岁,平均63．4岁。病变位于左侧5例,右侧7例,双侧1例。肿瘤位于输尿管中段1例,下段12例。所有患者均经手术治疗,术后随访通过患者定期门诊复查及电话随访完成。结果13例患者中行输尿管肿瘤切除＋输尿管端端吻合术4例,输尿管末端及膀胱袖套状切除＋输尿管膀胱再植术8例,1例双侧输尿管癌患者行左侧输尿管肿瘤切除＋输尿管端端吻合和右侧输尿管末端及膀胱袖套状切除＋右侧输尿管膀胱再植术。所有手术均未出现尿漏、出血等严重的并发症。肿瘤标本最大直径为0．6～1．9cm,平均1．7cm,病理均提示为尿路上皮癌,其中T1G1期6例,T2G1期2例,T1G2期2例,T2G2期1例,T1G3期2例。术后13例患者随访时间1～6年,平均随访时间3．5年。双侧输尿管癌患者术后9个月复查输尿管镜时发现左侧输尿管端端吻合处肿瘤复发,术中使用钬激光烧灼肿瘤,目前密切随访中;1例高级别尿路上皮癌患者死于肿瘤全身多发性转移;1例患者死于脑梗塞;其余患者目前均无复发征象。结论对于肿瘤分期和分级较低、体积较小和位于输尿管中下段的输尿管癌患者,保留肾脏术式是可以选择的手术方式,特别适合不能耐受较大手术、慢性肾功能不全、孤立肾或双侧输尿管癌患者。     

Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery

BACKGROUND: Dissimilarities in management and outcomes exist between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB). OBJECTIVE: The aim of this study was to analyze the stage-specific impact of upper or lower urinary tract tumor location on oncologic outcomes. DESIGN, SETTING, AND PARTICIPANTS: Data were collected from 4335 patients with UCB treated with radical cystectomy (RC) and bilateral pelvic lymphadenectomy (PLND), 877 patients with ureteral UTUC, and 1615 with pelvicalyceal UTUC treated with radical nephroureterectomy (RNU). No patient received preoperative chemotherapy or radiation therapy. INTERVENTIONS: Patients were treated with RC and bilateral PLND or RNU. MEASUREMENTS: Outcomes were assessed according to primary tumor location. RESULTS AND LIMITATIONS: Compared to UTUC patients, UCB patients had more advanced tumor stage and higher grade, and they were more likely to harbor lymphovascular invasion (LVI) and lymph node metastasis (p<0.001). In non-muscle-invasive tumor stages, UCB patients were more likely to experience disease recurrence and mortality compared to renal pelvicalyceal tumor patients (p<0.002) but not ureteral tumors (p>0.05). In pT2 and pT3 tumors, there was no difference in outcomes between the three tumor locations. In pT4 tumors, patients with ureteral and pelvicalyceal tumors were more likely to experience disease recurrence and mortality compared to UCB patients (p<0.004). These stage-specific findings were unchanged after adjustment for the effects of age, gender, tumor grade, LVI, lymph node status, and adjuvant chemotherapy. This study is limited by its retrospective and multicenter nature. CONCLUSIONS: Stage-specific differences in outcomes exist between UCB and UTUC. The differentially worse outcomes by stage between UCB and UTUC patients underline the differences between both cancer entities and the need for individualized stage-specific management for each patient.     

Tumor recurrence incidence following hand-assisted laparoscopic nephroureterectomy.

BACKGROUND AND OBJECTIVES: We evaluated the incidence of tumor recurrence following hand-assisted laparoscopic nephroureterectomy (HALNU) for the treatment of upper tract urothelial carcinoma. METHODS: The medical records of consecutive patients who underwent HALNU by a single surgeon (CW) between October 2001 and May 2005 were reviewed. The ureter was clipped before kidney dissection to prevent distal migration of tumor. Following liberation of the kidney, the bladder cuff and intramural ureter were excised by using a Collings knife under cystoscopic guidance. RESULTS: Ten patients were identified. The primary location of disease was confined to the intrarenal collecting system. Eight high-grade (HG) and 2 low-grade (LG) tumors were removed, with pT3 (6), pT2 (1), pT1 (1), and pTa (2) disease. The patient having a LG pTa urothelial carcinoma developed pulmonary metastasis 20 months following surgery and survived an additional 26 months. Two patients, each having a HG pT3 tumor, developed a urothelial carcinoma in the bladder contralateral to the site of ureteral excision. At a mean follow-up of 41 months, there has been no evidence of tumor recurrence in the pelvis. CONCLUSION: Our technique of HALNU does not appear to harbor an increased risk for urothelial carcinoma recurrence.     

Percutaneous management of renal pelvic urothelial tumors: long-term followup

PURPOSE: We present the long-term outcome of percutaneous resection of renal urothelial tumor. MATERIALS AND METHODS: A total of 24 patients underwent primary percutaneous resection of renal urothelial tumor. Patients with low stage pT0-1 disease were treated primarily with percutaneous surgery. All pelvicaliceal tumors were taken for biopsy and treated with percutaneous resection. Patients with multi-segmental pelvicaliceal system involvement, stage greater than pT1, high grade histology or additional ureteral tumors were considered for nephroureterectomy. Topical chemotherapy (mitomycin C or epirubicin) was administered via nephrostomy tube or intravesical instillation after Double-J stent (Medical Engineering Corp., New York, New York) insertion. Surveillance included upper tract cytology, nephroscopy or fiberoptic ureterorenoscopy. Long-term followup was correlated with histopathology. RESULTS: Of the 24 cases 2 had squamous cell carcinoma, 5 had grade III transitional cell carcinoma, 15 had grade I to II transitional cell carcinoma and 2 had no tumor. Control was established with initial percutaneous resection in 18 (75%) cases and second look nephroscopy in 4. Early recurrences were detected by excretory urography (IVP) in 3 cases, small pelvic recurrences by IVP in 2, fiberoptic ureterorenoscopy in 2 and bladder tumors by flexible cystoscopy in 3 after 1 year. A total of 10 nephroscopies were performed in 5 cases, 24 flexible uretereorenoscopies in 9 and IVP in 6. Three synchronous, grade I bladder tumors were managed conventionally. All patients with high grade disease died of malignancy except one (with no further treatment) and 6 of the 15 patients with low grade noninvasive transitional cell carcinoma underwent nephroureterectomy during followup either due to progression of disease, concomitant tumor or complications. Two patients with solitary kidneys died of renal failure unrelated to malignancy. High grade tumors or tumors greater than T1 were treated with nephroureterectomy early during management. There was no perioperative mortality and 9 (60%) of the low grade cases the kidneys were preserved at a mean followup +/- SD of 64 +/- 15 months. All excised tracks from patients who underwent nephroureterectomy and the renal fossae were free of tumor on histopathological examination. CONCLUSIONS: Percutaneous resection of transitional cell tumor should be considered primarily in patients with early stage disease excluding tumors crossing caliceal infundibula, ureteropelvic junction tumor, tumor extending over multiple calices and synchronous ureteral tumors. The long-term outcome of low grade tumors is good and they should be managed by either form of minimally invasive surgery. Nephron sparing is possible in a large percentage of low grade disease but high grade tumors should be treated with nephroureterectomy.     

原发性输尿管癌29例报告

为提高原发性输尿管癌的诊治水平，在１９８２－１９９６年收治的２９例原发性尿管癌患者的诊断、治疗情况进行临床分析，结果有２４例术前确诊，９例手术后１－３年死于肿瘤部复发或转移，３例手术后３－５年死于非肿瘤疾病。预后与肿瘤分期及分级相关，其中分期更为重要。     

Clinical and pathological study of renal pelvic and ureteral tumors

This report is on 25 patients with primary urothelial tumor in the upper urinary tract who were admitted to our hospital from February, 1969 through January, 1983. The patients were 18 males and 7 females with a mean age of 66 years. The affected side was the right side in 11 cases, the left side in 12 and bilateral in 1 case (bilateral asynchronous ureteral tumor). The major symptoms were hematuria (69%) and flank pain (25%), with rare signs of fever. Total nephroureterectomy with bladder cuff was employed as the surgical method in 19 out of 25 cases. We performed conservative surgery in the case of non-infiltrating bilateral ureteral tumor. Pathologically, all 25 patients had transitional cell carcinoma. Over-all survival rate at 3 and 5 years was 64% and 51%, respectively. Our findings coincided with earlier reports by others that the prognosis of primary tumors in the upper urinary tract is related to the grade and stage of the tumor.     

Superficial transitional cell carcinoma of the ureteral orifice: Higher risk of developing subsequent upper urinary tract tumors

AIM: Reports specifically addressing transitional cell carcinoma (TCC) of the ureteral orifice are scarce. This paper presents our experiences of such tumors, including the characteristics of the disease and the incidence of subsequent upper urinary tract recurrence. METHODS: This study included 572 new cases of TCC of the urinary bladder diagnosed in our institute during a period of 5 years. Thirty-one (5.4%) patients had superficial tumors involving ureteral orifices. All 31 patients underwent transurethral resection of the bladder tumors, including the involved ureteral orifices. After the surgery, patients received regular follow up with cystourethroscopy, urine cytology and periodic intravenous pyelography (IVP). Ureterorenoscopy was performed in cases of suspicious IVP or urine cytology findings. RESULTS: Thirty-one patients with superficial tumors involving the ureteral orifice were followed up for 5-8 years or until death. The pathological stage was Ta in 16 cases and T1 in 15 cases. Bladder tumor recurrence was noted in three (18.8%) of the pTa patients and in seven (46.7%) of the pT1 patients. Subsequent upper urinary tract tumors developed in four (12.9%) patients between 33 and 67 months (mean: 33.5) after the first transurethral resection. All four cases of upper tract recurrence had pT1 primary bladder tumor, which recurred for 1-3 times (mean 1.8) before upper tract recurrence. None of these patients had ureteral stenting after bladder tumor resection. Three of four patients with upper tract recurrence had single lower ureteral tumor, while the remaining one patient had multiple tumors. Patients with subsequent upper urinary tract tumors underwent nephroureterectomy and bladder cuff excision. One died of the disease; the other three cases were free of the disease after the therapy. CONCLUSIONS: Patients with primary superficial bladder transitional cell carcinoma involving the ureteral orifice have a higher risk of developing subsequent upper urinary tract tumors, particularly for pT1 primary bladder tumors. Frequent and close follow up is recommended.     

肾盂鳞状细胞癌临床特点分析

目的 探讨肾盂鳞状细胞癌的诊治特点.方法 回顾性分析1991年10月至2009年5月收治8例肾盂鳞状细胞癌患者资料.临床表现血尿8例,腰痛7例,腹部包块1例.B超检查8例,IVU检查8例,CT检查4例.术前诊断为肿瘤3例,诊断为肾结石5例,结石术中发现肿瘤并经冰冻病理确诊2例.8例患者均经手术治疗,行根治性肾输尿管切除4例、单纯性肾切除3例、姑息性切除术1例.结果 8例病理诊断均为鳞状细胞癌.中分化6例,高分化和低分化各1例;pT1 1例,pT2 1例,pT3 3例,pT4 3例;淋巴结转移2例.获随访7例,失访1例.术后生存时间2～42个月,中位时间6个月,患者均死于肿瘤复发及转移.结论 肾盂鳞状细胞癌恶性程度高,常合并结石,术前诊断困难,确诊时多为中晚期,术后短期内易复发转移,预后极差.

Abstract：

Objective To review the diagnosis and treatment of squamous cell carcinoma of renal pelvis. Methods The clinical data from October 1991 to May 2009 of eight cases of squamous cell carcinoma of renal pelvis were reviewed and analyzed retrospectively. The symptoms of the patients were hematuria (eight cases), pain (seven cases) and abdominal mass (one case). All patients underwent B-ultrasound and IVU examination and four cases underwent CT scan. Three cases were diagnosed as having a tumor before surgery. Five cases were diagnosed as renal calculus, two of the five cases were diagnosed by intraoperative frozen section. Radical nephroureterectomy were performed in four cases, nephrectomy in three cases and palliative resection in one case. Results Histological classification revealed that six cases were moderately differentiated, one case was well differentiated and one case was poorly differentiated. Two cases had stage pT1/pT2 and six cases had stage pT3/pT4. 2 cases had regional lymph nodes metastasis. Seven cases were followed-up. All patients died of tumor recurrence or metastasis. The median tumor specific survive time was six months (range from two months to 42 months). Conclusions Squamous cell carcinoma of renal pelvis is often occurs concurrently with urolithiasis which could lead to difficulty in diagnose before operation. As the most of the patients were diagnosed with advanced stage disease, squamous cell carcinoma of renal pelvis tended to early recurrence and metastasis and the prognosis was very poor.     

Nephron-sparing surgery with autotransplantation for high-grade upper urinary tract urothelial carcinoma in a patient with solitary kidney

Instead of nephroureterectomy with bladder cuff excision, nephron-sparing surgery can be considered in selected patients with non-muscle invasive upper urinary tract urothelial carcinoma. The role of kidney-sparing surgery has been established for the management of low-grade urothelial carcinoma. We report a solitary kidney patient with high-grade renal pelvis urothelial carcinoma treated with nephron-sparing surgery by ex vivo tumor excision and autotransplantation. The results of the surgery were excellent.